GC Cell Co-CEOs Kim Jae-wang and Won Sung-yong announced on the 31st that it has filed a 특허 출원 related to 면역치료 for the 치료 of 고형암. This is a 파이프라인 developed based on GC Cells CAR-NK 플랫폼, targeting CLDN18.2, and is considered a significant expansion of its applicability to the 분야 of 고형암.
특허 출원 for Solid Cancer-Targeting CAR-NK 기술
GC Cell recently filed a 특허 출원 for 면역치료 기술 aimed at treating 고형암. This 특허 was developed by utilizing GC Cells proprietary CAR-NK Chimeric Antigen Receptor-Natural Killer cell 플랫폼 to target a specific 단백질, CLDN18.2.
This 기술 is highly significant because it extends beyond the limitations of existing 면역치료제, which primarily targeted 혈액암, to expand applicability to the challenging 분야 of 고형암. Through this 특허, GC Cell aims to gain a competitive 우위 in the 개발 of solid cancer 치료제.
CLDN18.2 단백질 Expressed in Major 고형암
CLDN18.2, the key target of this 기술, is known to be a 단백질 commonly expressed in various 고형암, including gastric cancer, pancreatic cancer, and esophageal cancer. This 단백질 has been identified as playing a crucial role in 암세포 성장 and is currently attracting significant 주목 as a new therapeutic 표적 in the global pharmaceutical and biotechnology 산업.
The 개발 of 치료법 targeting CLDN18.2 is expected to offer new 치료 옵션 for 환자 with 고형암. GC Cells 특허 출원 is analyzed to be in line with these global 연구 동향.
Strengths and Expandability of CAR-NK 치료제
Unlike CAR-T Chimeric Antigen Receptor-T cell 치료제, which use a 환자s own 세포, CAR-NK 치료제 utilize 세포 from healthy 기증자. This characteristic offers the 장점 of being developed as a mass-producible, off-the-shelf 치료제.
Furthermore, high 안전성 is expected based on the innate immune 특성 of NK 세포. It is regarded as an 대안 that can contribute to reducing 치료 비용 and improving 환자 접근성 through 효율성 in 생산 and 공급.
Strengthening Global 경쟁력 and Continued 연구 개발
Won Sung-yong, CEO of GC Cell, stated, This 특허 is one of the continuous 성과 in the 연구 개발 of our CAR-NK 플랫폼-based solid cancer 파이프라인.
GC Cell announced its 계획 to continue pursuing relevant 연구 개발 to further strengthen its global 경쟁력.
Through this 특허 출원, GC Cell is expected to secure a leading 입지 in the 분야 of solid cancer 면역치료 and provide innovative 치료 대안 to solid cancer 환자 worldwide. GC Cell 계획 to continue leading the next-generation 세포 치료제 시장 through ongoing 연구 개발.
